ARGENTA
Argenta, the only combined global contract research organization (CRO) and contract development & manufacturing organization (CDMO) dedicated to animal health, announced today that it has acquired Klifovet, the leading CRO and Regulatory Affairs consultancy organization in Europe. Financial details of the transaction were not disclosed. Klifovet founder and CEO Dr. Klaus Hellmann will continue to lead Klifovet and will join Argenta’s senior leadership team.
Founded in 1997 by Dr. Klaus Hellmann and located in Munich, Germany, Klifovet has built a leading reputation in the animal health industry, providing extensive expertise in clinical research and regulatory affairs. Its ~50 employees have had successful involvement in hundreds of studies, and their expertise and knowledge has been critical to numerous marketing authorizations for pharmaceutical, biological, immunological, and novel therapies. Its client base comprises the world’s top animal health and nutrition companies as well as many promising startups.
“The acquisition of Klifovet, and the expansion into the EU, is part of Argenta’s growth strategy and provides our customers the opportunity for a seamless, global Molecule to Market product development experience,” said Ben Russell, CEO of Argenta. “Importantly, Argenta and Klifovet share strategic and cultural values built around customer excellence, teamwork, partnership, and innovation. I am very pleased to welcome Klifovet as a valued member of the Argenta Group and collectively work to continue to advance animal health to the benefit of our clients.”
The combined business will be a global, full-value strategic partner, stimulating innovation and supporting large and small animal health and nutrition companies. Klifovet will particularly complement Argenta's Clinical & Regulatory Services team based in the United States, offering an unparalleled level of expertise, and access to the largest transatlantic CRO capability in animal health.
“Joining forces with the Argenta Group is 100% in line with Klifovet’s vision of becoming the leading international full-service provider for the development and maintenance of products for animal health, nutrition and wellbeing. The two leading CROs, with a presence in the EU and US, combined with the know-how and capabilities in manufacturing, regulatory services, project management, and product development, create the world’s leading animal health CDMO and CRO. It provides unique and excellent opportunities for both our clients and employees. I am truly convinced this to be a perfect fit and look forward to a great future within the Argenta Group,” said Klaus Hellmann, CEO of Klifovet.
Argenta was advised on the transaction by Stonehaven Consulting AG, a global consulting firm focused on animal health.
About Argenta
Founded in 2006 in New Zealand, Argenta’s talented, diverse and committed employees work on a daily basis to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, Argenta holds a unique position as the only combined global contract research organization (CRO) and contract development & manufacturing organization (CDMO) dedicated to animal health. Argenta operates from “Molecule to Market” in partnership with customers of all sizes from all corners of the world, supporting their Research & Development, clinical research, regulatory, scale up and manufacturing needs along their veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com
About Klifovet
Klifovet AG, based in Munich, Germany, was founded in 1997 and is a full-service Contract Research and Development Organization (CRO), offering regulatory affairs, pre-clinical and clinical studies, GMP compliant manufacturing including clinical supplies, quality assurance, data management and statistical analyses for the animal health and nutrition industry. Where relevant, the organization assures that services comply with VICH GCP, GLP, GCP, GMP, GPhVP and ISO 9001 requirements. Klifovet supports its clients in all aspects of the development and maintenance of products for the animal health and nutrition market. For more information about Klifovet, please visit www.klifovet.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005309/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 01:00:00 CET | Press release
Venture Global’s fourth long-term contract with a Japanese company7.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade o
Airship Study: No-Code Native App Experiences Double Purchase Frequency (+140%), Offering Path to Profitable Holiday Growth26.11.2025 00:08:00 CET | Press release
New research quantifies the massive conversion lift from optimizing native app and web experiences, providing a critical no-code path for retailers to drive profitability Mobile-first customer experience company Airship today released new aggregate data analysis findings showing that no-code native app experiences significantly increase conversion for key lifecycle events and more than double purchase frequency. The Airship "Experience Impact” research, which studied over 1,000 in-app retail experiences and 1.7 billion device sessions, quantifies the impact of optimizing end-to-end customer journeys—not just sending messages—using no-code and AI-powered tools to drive loyalty and retention at scale, leading to sustainable profitability in a volatile economic environment. Key Findings Customers exposed to high-impact no-code native app experiences such as optimized onboarding flows, dynamic surveys, or embedded personalized offers, purchase 140% more frequently than app customers who do
Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology25.11.2025 17:30:00 CET | Press release
Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company). In a 2024 lawsuit filed in the UPC (proceedings no. UPC CFI 187/2024), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European patents (EP) 2,500,439 and 1,910,572. The Court in its judgment of 18 November 2025 has rejected that claim and dismissed all of Advanced Cell Diagnostics' lawsuit, ruling that the patents are not infringed either literally or by equivalence (UPC Judgment). This 2025 UPC judgment follows on the heels of an April 2024 UK judgment in which the High Court of England and Wales had already dismissed an earlier infringement lawsuit by revoking the UK parts of the same two Advanced Cell Diagnostics patents (proceedings no. HP-2022-000026), ruling that they wer
Pure Lithium Receives Saudi Patent for Vertically Integrated Lithium Metal Battery Technology25.11.2025 14:20:00 CET | Press release
Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the Kingdom of Saudi Arabia has granted the company a foundational patent titled “Vertically Integrated Pure Lithium Metal Production and Lithium Battery Production.” This broad patent covers technology that combines lithium extraction, anode production and battery manufacturing. Pure Lithium’s Brine to Battery™ is a registered trademark in the Kingdom of Saudi Arabia, planting a strong base of intellectual property in the region. “The technology is particularly relevant to Saudi Arabia because it is one of the places in the world with lithium-containing brines, and even has an abundance of vanadium, which is used in our second-generation battery,” said Founder, Chairman and CEO Emilie Bodoin. “In order to displace today’s lithium-ion battery, our vision is to create global battery hubs with closed loop supply chains, not just in the U.S., but in the many places in the world whe
‘BLUE LOCK - TOKYO EGOIST -’ kicks off on Saturday, November 2225.11.2025 14:07:00 CET | Press release
“BLUE LOCK” voice actors Kazuki Ura and Hiroshi Kamiya were also blown away by the spectacle! A countdown to the new release was held together with over 2,000 fans gathered at the Tokyo Metropolitan Government Plaza. In its efforts to promote nighttime tourism, the Tokyo Metropolitan Government is developing new attractions that illuminate the capital after dark. As part of this initiative, projection mapping is being presented year-round on the iconic Tokyo Metropolitan Government Building No. 1, transforming its façade into a canvas of light and sound. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251121922505/en/ ©Muneyuki Kaneshiro, Yusuke Nomura, KODANSHA/BLUE LOCK Production Committee. A brand-new production inspired by the internationally popular soccer anime“BLUE LOCK”, titled BLUE LOCK – TOKYO EGOIST –, began screening on Saturday, November 22. On the first day of the screening, a mini-event was held at the Tokyo M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom